Production of two recombinant insulin-like growth factor binding protein-1 subtypes specific to salmonids.


Journal

General and comparative endocrinology
ISSN: 1095-6840
Titre abrégé: Gen Comp Endocrinol
Pays: United States
ID NLM: 0370735

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 11 06 2020
revised: 16 08 2020
accepted: 24 08 2020
pubmed: 6 9 2020
medline: 20 4 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

Salmonids have four subtypes of insulin-like growth factor binding protein (IGFBP)-1, termed -1a1, -1a2, -1b1 and 1b2, owing to teleost- and a lineage-specific whole-genome duplications. We have previously produced recombinant proteins of masu salmon IGFBP-1a1 and -1b2 and conducted functional analysis. To further characterize salmonid-specific IGFBP-1s, we cloned cDNAs encoding mature proteins of IGFBP-1a2 and -1b1 from the liver of masu salmon (Oncorhynchus masou). IGFBP-1a2 and -1b1 shared a 56% amino acid sequence homology whereas their homologies with their counterparts (i.e. -1a1 and -1b2) were 77% and 82%, respectively. We next expressed recombinant masu salmon (rs) IGFBP-1a2 and -1b1 with fusion partners thioredoxin (Trx) and a His-tag using the pET-32a(+) vector system in Escherichia coli. Trx.His.rsIGFBP-1s were detected in the insoluble faction, solubilized in a buffer containing urea, and isolated by Ni-affinity chromatography. They were refolded by dialysis and cleaved from the fusion partners by enterokinase. rsIGFBP-1a2 and -1b1 were purified by reversed-phase high performance liquid chromatography. Purified rsIGFBP-1a2 and -1b1 had the ability to bind digoxigenin-labeled human IGF-I on ligand blotting. We then examined the effects of rsIGFBP-1a1, -1a2, -1b1 and -1b2 in combination with human IGF-I on growth hormone (GH) release from cultured pituitary cells of masu salmon. IGF-I alone reduced GH release while the addition of rsIGFBP-1a1, -1b1 or -1b2, but not rsIGFBP-1a2, diminished the suppressive effect of IGF-I. Addition of rsIGFBP-1s without IGF-I had no effect on GH release. These results show that rsIGFBP-1b1, along with rsIGFBP-1a1 and -1b2, inhibits IGF-I action on the pituitary in masu salmon. The lack of the effect by rsIGFBP-1a2 suggests that salmon IGFBP-1 subtypes underwent subfunction partitioning and have different degrees of IGF-inhibitory action.

Identifiants

pubmed: 32890480
pii: S0016-6480(20)30359-2
doi: 10.1016/j.ygcen.2020.113606
pii:
doi:

Substances chimiques

Insulin-Like Growth Factor Binding Protein 1 0
Protein Isoforms 0
Recombinant Proteins 0
Human Growth Hormone 12629-01-5
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113606

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Ryuya Hasegawa (R)

Graduate School of Environmental Science, Hokkaido University, Kita 10, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-0810, Japan.

Takuto Miura (T)

Graduate School of Environmental Science, Hokkaido University, Kita 10, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-0810, Japan.

Nobuto Kaneko (N)

Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate 041-8611, Japan.

Ryousuke Kizaki (R)

Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate 041-8611, Japan.

Gakuto Oishi (G)

Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate 041-8611, Japan.

Hanae Tanaka (H)

Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate 041-8611, Japan.

Moe Sato (M)

Graduate School of Environmental Science, Hokkaido University, Kita 10, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-0810, Japan.

Munetaka Shimizu (M)

Graduate School of Environmental Science, Hokkaido University, Kita 10, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-0810, Japan; Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate 041-8611, Japan. Electronic address: mune@fish.hokudai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH